Naloxone Could Go OTC
This article was originally published in RPM Report
Executive Summary
A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.
You may also be interested in...
Naloxone Behind-the-Counter? Petition Could Help Push Action
The idea of “behind-the-counter” may be behind the times, but a request to put naloxone there could help push FDA’s existing interest in expanding access to the overdose antidote.
FDA Approves Easy-To-Use Naloxone: Antidote to Zohydro?
FDA’s recent approval of an auto-injection form of naloxone may be an opportunity to change the public perception of the agency’s priorities in the opioid and prescription drug abuse debate.
Plan B One-Step OTC Proposal Leaves Plaintiffs, Judge Korman Wary
The Center for Reproductive Rights and other plaintiffs suing FDA say the agency’s plan to approve only Teva’s Plan B One-Step for universal OTC sales, but not less-expensive generic emergency contraceptives, would not provide sufficient access for all women.